SS 26 - Sarcoma 1: Optimizing Treatment Outcomes in Soft Tissue Sarcoma and Melanoma

Moderator(s)

• 

  Elizabeth Baldini, MD, FASTRO, MPH, FASTRO

  Brigham and Women's Hospital/Dana-Farber
  Boston, MA
• KS

  Kilian Salerno, MD

  Radiation Oncology Branch, National Cancer Institute
  Bethesda, MD

Presentations:

• 5:00 PM – 5:10 PM ET

  A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-Up and Outcomes
  

  Presenter: John Nikitas, MD – UCLA Radiation Oncology
• 5:10 PM – 5:20 PM ET

  The Impact of Hypofractionated Pre-Operative Radiation Therapy on PD-L1 Expression in Soft Tissue Sarcomas
  

  Presenter: Manpreet Bedi, MD, MS – Medical College of Wisconsin Affiliated Hospitals
• 5:20 PM – 5:30 PM ET

  Habitat Escalated Adaptive Therapy (HEAT): A Phase 2 Trial Utilizing Radiomic Habitat-Directed and Genomic-Adjusted Radiation Dose (GARD) Optimization for High-Grade Soft Tissue Sarcoma
  

  Presenter: Arash Naghavi, MD, MS – H. Lee Moffitt Cancer Center and Research Institute
• 5:30 PM – 5:40 PM ET

  Reduction of Bone Fracture after Radiotherapy in Lower Extremity Soft Tissue Sarcoma after Implementing Bone Avoidance Objectives for Radiotherapy Planning
  

  Presenter: David Kirsch, MD, PhD, FASTRO – Princess Margaret Cancer Centre
• 5:40 PM – 5:50 PM ET

  Immune Profiling of "Radvax" Abscopal Responses in Metastatic Melanoma Patients Progressing on Anti-PD1 Therapy Treated with Hypofractionated Radiotherapy (HFRT) to One Lesion Combined with Pembrolizu
  

  Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
• 5:50 PM – 6:00 PM ET

  Discussant
  

  Discussant: B. Ashleigh Guadagnolo, MD, FASTRO, MPH – MD Anderson Cancer Center